Pay in 4 interest-free payments of $7.22 Learn more
Ships within 48 hours · Estimated delivery Nov 2 - Nov 7
17-19 November 2026 18-20 May 2027 To proceed please sign up (free buyer account) or log in (if you already have an account)
All the mice (68 weeks) were maintained in a pathogen-free environment with ad libitum access to food and water, and a suitable temperature range of 2025 C and 5065% relative humidity
Benefits & Risks (Clinical Study Framing) Observed Benefits in Trials Dose-dependent weight reduction Improvements in waist circumference Appetite reduction Observed Risks Sympathetic activation (heart rate increase) Gastrointestinal symptoms Sleep disturbance Dry mouth Risk increased at higher dose arms Lifestyle Factors Who It Was Studied In The primary obesity trial involved: Adults with obesity Structured dietary intervention Controlled monitoring setting It was not studied in: Pediatric populations Cardiovascular-unstable patients Long-term open population settings Comparative Positioning Tesofensine differs from: GLP-1 receptor agonists incretin-based appetite modulation GIP/GLP dual agonists metabolic hormone modulation Sympathomimetic stimulants shorter half-life stimulant models Its long half-life and monoamine modulation profile make it pharmacologically distinct
Acetomenaphine depletes glutathione in the liver and contributes to liver damage
doi: 10.1172/jci.insight.89376 185 HoelFHoelAPettersenIKRekelandIGRisaKAlmeKet al
Let the powder dissolve completely
US$ 20.58
US$ 21.75
US$ 20.73
US$ 23.63
US$ 20.49